Table 1.
First author | Publication year | Country | Design | Sample | Main outcomes |
---|---|---|---|---|---|
Sparks et al.26 | 2018 | United States | Prospective cohort | 843 women with RA versus 8,399 controls | Incidence of COPD in RA patients: 8.1% COPD risk in RA: HR 1.68 (95% CI: 1.36–2.07) smoking, BMI, dietary quality and physical activity adjusted |
Ungprasert et al.25
|
2016 | Systematic meta-analysis21–24 | 32,675 patients with RA versus 122,204 controls | COPD risk in RA: RR 1.99 (95% CI: 1.61–2.45) | |
Dougados et al.28 | 2013 | International | Cross-sectional | 3,920 patients with RA | COPD prevalence in RA: lower in Asia (Japan, 1.4%; Korea, 1.3%; Taiwan, 0.3%) than in Europe and the United States (Hungary, 8.0%; the United States, 7.5%) |
Norton et al.27 | 2013 | United Kingdom | Inception cohort | 1,460 patients with RA versus general population | COPD annual incidence in RA: 0.4 (95% CI: 0.3–0.5); 15-year COPD cumulative incidence in RA: 5.0 (95% CI: 3.7–6.8); COPD prevalence in RA: 2.1% (95% CI: 1.4–2.9) |
Bieber et al.29 | 2013 | Israel | Cross-sectional | 9,039 patients with RA versus 15,070 controls | COPD prevalence in RA: OR 1.98 (95% CI: 1.77–2.21, p = <001), adjustments: age, sex, socioeconomic status, smoking, obesity |
Sharif et al.39 | 2018 | Israel | Cross-sectional | 4,076 patients with AS versus 20,290 controls | COPD in AS: OR 1.225 (p = 0 03) adjusted for age, gender, and smoking |
Khraishi et al.38 | 2011 | Canada | Prospective cohort | 165 patients with PsA | COPD prevalence PsA: 11.5% (early PsA). 9.4% (established) |
Hemminki et al.21 | 2011 | Sweden | Registry-based | 297,300 patients | Incidence of COPD in AS (SIR 1.72; 95% CI: 1.23–2.33) Incidence of COPD in RA (SIR 2.57; 95% CI: 2.21–2.97) |
COPD: chronic obstructive pulmonary disease; RA: rheumatoid arthritis; PsA: psoriatic arthritis; AS: angylosing spondylitis; RR: risk ratio; HR: hazard ratio; IRR: incidence rate ratio; SIR: standardized incidence ratio; BMI: body mass index; OR: odds ratio; CI: confidence interval.